Evidence map›Paper›PMID 34590195›Full record

ArticleAAPS PharmSciTech2021

Primaquine Loaded Solid Lipid Nanoparticles (SLN), Nanostructured Lipid Carriers (NLC), and Nanoemulsion (NE): Effect of Lipid Matrix and Surfactant on Drug Entrapment, in vitro Release, and ex vivo Hemolysis.

Kai-Wei Wu, Corinne Sweeney, Narendar Dudhipala, Prit Lakhani, Narayan D Chaurasiya, Babu L Tekwani, Soumyajit Majumdar

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AAPS PharmSciTech, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 74 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kai-Wei WuDepartment of Pharmaceutics and Drug Delivery, The University of Mississippi, 111 Faser Hall, University, MA, 38677, USA.
Corinne SweeneyDepartment of Pharmaceutics and Drug Delivery, The University of Mississippi, 111 Faser Hall, University, MA, 38677, USA.
Narendar DudhipalaDepartment of Pharmaceutics and Drug Delivery, The University of Mississippi, 111 Faser Hall, University, MA, 38677, USA.
Prit LakhaniDepartment of Pharmaceutics and Drug Delivery, The University of Mississippi, 111 Faser Hall, University, MA, 38677, USA.
Narayan D ChaurasiyaDepartment of Infectious Diseases, Division of Drug Discovery, Southern Research, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA.
Babu L TekwaniDepartment of Infectious Diseases, Division of Drug Discovery, Southern Research, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA.
Soumyajit MajumdarDepartment of Pharmaceutics and Drug Delivery, The University of Mississippi, 111 Faser Hall, University, MA, 38677, USA. majumso@olemiss.edu.
University of Mississippi · USSouthern Research Institute · US

Funding

Pilot Project ProgramP30GM122733 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI MAJUMDAR, SOUMYAJIT · 2018 to 2022
$5.3M
Nano-carrier Formulations for Targeted Drug Delivery and Malaria Radical CureR01AI132579 · NIAID · UNIVERSITY OF MISSISSIPPI · PI TEKWANI, BABU L · 2017 to 2020
$2.8M
NIAID NIH HHS R01 AI132579NIGMS NIH HHS P30 GM122733
6 · The paper itself

Abstract

Primaquine (PQ), an 8-aminoquinoline antimalarial drug, has been widely used for the eradication of hypnozoites from the liver and, therefore, recognized as the radical cure of malaria. However, the clinical applications of PQ are restricted to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to severe dose-related hemolytic side effects. Nanoparticle carriers have shown great potential in achieving higher PQ concentrations in the target site, thereby reducing dose-related systemic toxicity caused by non-specific exposure. This work aims to develop, compare, and evaluate three PQ-loaded lipid-based drug carriers including solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and nano-emulsions (NE). The optimized PQ-SLN, PQ-NLC, and PQ-NE had a particle size of 250 nm, a PDI range of 0.1 to 0.3, a zeta potential of - 30 mV, and entrapment efficiency of ~ 90%. All lipid formulations showed sustained release in both simulated gastric and intestinal fluids over 6 h. Four empirical models - including zero-order, Higuchi, Korsmeyer-Peppas, and Hixson-Crowell models - were tested to understand the drug release mechanisms of PQ-SLN, PQ-NLC, and PQ-NE. The model fitness was found to be the highest in the Korsmeyer-Peppas model for all the PQ-loaded lipid formulations (R

Indexed as

Drug CarriersNanoparticlesPrimaquineEmulsionsHemolysisHumansLipidsParticle SizeSurface-Active AgentsDrug CarriersEmulsionsLipidsPrimaquineSurface-Active AgentsEx vivo hemolysisIn vitro releaseLipid-based formulation(s)Particle sizePrimaquineStability

Identifiers

PMID34590195
PMCPMC9178661
OpenAlexW3202197765

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.